Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
NCT03463460Phase 2Active, not recruiting
- Start
- Jun 2018
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, sunitinib in thymic carcinoma (TC). Started Jun 2018; status: active, not recruiting.
02
Drugs
pembrolizumabsunitinib
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT03463460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463460.